Genentech’s (DNA) for Q2 hit $3 billion, up from $2.2 billion in the same quarter last year. Operating income hit $1.1 billion up from $.75 billion last year.
Big winners in the company’s drug portfolio were Avastin with sales up 33% to $564 million in US product sales and Lucentis, introduced recently with sales of $209 million.
Sales of the company’s No.1 product, Rituxan, were up 11% to $562.
The shares traded flat after hours.
Douglas A. McIntyre
An
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
